Comparative Pharmacology
Head-to-head clinical analysis: MYCELEX versus TERAZOL 3.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MYCELEX versus TERAZOL 3.
MYCELEX vs TERAZOL 3
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clotrimazole, an imidazole antifungal, inhibits fungal cytochrome P450 14α-demethylase, thereby disrupting ergosterol biosynthesis and compromising fungal cell membrane integrity.
Terconazole is an azole antifungal agent that inhibits fungal cytochrome P450 14α-demethylase, thereby blocking the conversion of lanosterol to ergosterol, an essential component of the fungal cell membrane. This disrupts membrane integrity and leads to fungal cell death.
For oropharyngeal candidiasis: Clotrimazole troche 10 mg dissolved slowly in mouth 5 times daily for 14 days. For vulvovaginal candidiasis: Clotrimazole vaginal tablet 500 mg single dose or 200 mg daily for 3 days or 100 mg daily for 7 days; 1% vaginal cream 5 g intravaginally daily for 7-14 days.
One applicatorful (approximately 5 g of 0.8% terconazole vaginal cream) intravaginally once daily at bedtime for 3 consecutive days.
None Documented
None Documented
Terminal elimination half-life is 20-50 hours (mean ~30 hours) in adults; prolonged in neonates (~40-80 hours) and in hepatic impairment.
The terminal elimination half-life after intravaginal application is approximately 4-6 hours, reflecting local retention and slow systemic absorption of the small absorbed fraction.
Primarily hepatic metabolism; <1% excreted unchanged in urine; ~50% of dose excreted in feces as metabolites.
Following intravaginal administration, terconazole is minimally absorbed (<5%) into systemic circulation. Absorbed drug is primarily metabolized in the liver and excreted via feces (approximately 50-60% as metabolites) and urine (approximately 20-30% as metabolites). Unabsorbed drug is excreted in feces.
Category C
Category C
Azole Antifungal
Azole Antifungal